Clinical Trial: A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Hepatocellular Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatment
Brief Summary:
The trial is designed as a single-arm, open-label, phase I study investigating an off-the-shelf, multi-peptide-base HCC vaccine plus Montanide, combined with Durvalumab in patients with very early, early and intermediate stage of HCC.The investigational agents will be applied without concomitant anti-tumour therapy with the intention to reduce risk of recurrence/progression in patients who have received all indicated standard treatments.
Read more